SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

George Frey—Getty Images

76

Merck

MRK

Merck started 2019 strong, grabbing $10.8 billion in global sales during the first quarter—an 8% increase year-over-year—and raising its full-year revenue range for the year. This builds off the $42.3 billion in global sales the pharmaceutical giant netted in 2018, a 5% increase from 2017. Merck’s blockbuster cancer immunotherapy drug Keytruda continues to shine amongst its portfolio. Accounting for nearly a quarter of the company’s pharmaceutical sales, Keytruda netted $2.3 billion in sales for the first quarter in 2019. Merck is currently looking forward to the results of additional Keytruda studies later this year.

Looking for leads, investment insights, or competitive intelligence?

CEO

Kenneth C. Frazier

CEO Title

Chairman, President & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Kenilworth, N.J.

Years on Fortune 500 List

65

Employees

69,000

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$42,2945.4%
Profits ($M)$6,220.0159.8%
Assets ($M)$82,637
Total Stockholder Equity ($M)$26,701
Profit Ratios
Profit as % of Revenues14.7%
Profits as % of Assets7.5%
Profits as % of Stockholder Equity23.3%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)2.32
EPS % Change (from 2017)166.7%
EPS % Change (5 year annual rate)9.6%
EPS % Change (10 year annual rate)-4.4%
Total Return
Total Return to Investors (2018)40.2%
Total Return to Investors (5 year, annualized)12.3%
Total Return to Investors (10 year, annualized)13.8%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck

Drugmakers Blame Middlemen for High Prices But Still Make Huge Profits

Out of more than 100 business sectors, drug companies are in the top 10 of profits.

Read More →
Fortune's Blue Ribbon Companies 2018

These 56 companies are on at least four of Fortune's 2018 rankings.

Read More →
The 5 Best Biotech and Health Care Stocks to Buy for 2019 Now That Congress Can’t Repeal Obamacare

With Congress split between Republicans and Democrats, pharma and biotech stocks are ready to surge.

Read More →